Watch SILO. Know when insiders buy.
One email the day a filing lands. Free.
SILO
Silo Pharma, Inc.
1.75
+0.00 +0.00%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.8MP/E —DIV YIELD —FCF YIELD —REV TTM $54K −25.0%NET INCOME −$4.5MNET CASH —52W 1.72 – 11.25SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$929K | −$833K | — | -0.76 | −$782K | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $18K | +0.0% | -14.8% | −$1.6M | −$1.6M | — | -0.12 | −$823K | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | $18K | +0.0% | -14.8% | −$787K | −$882K | — | 0.00 | −$780K | — | — | Mar 27 |
| Q3 2025 · Sep 30 | $18K | +0.0% | -14.8% | −$1.2M | −$1.1M | — | -0.12 | −$955K | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $18K | +0.0% | 91.9% | −$1.2M | −$1.2M | — | -2.88 | −$1.3M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | $18K | +0.0% | 91.9% | −$1.1M | −$1M | — | -0.23 | −$1.6M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | $18K | +0.0% | 91.9% | −$1.8M | −$1.7M | — | -0.41 | −$917K | — | — | Mar 27 |
| Q3 2024 · Sep 30 | $18K | +0.0% | 91.9% | −$1M | −$929K | — | -0.22 | −$1.3M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $18K | — | 91.9% | −$1M | −$932K | — | -0.31 | −$732K | — | — | Nov 13 |
| Q1 2024 · Mar 31 | $18K | — | 91.9% | −$880K | −$802K | — | -0.28 | −$838K | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | $18K | — | 91.9% | −$1.2M | −$1.1M | — | -0.38 | −$910K | — | — | Mar 28 |
| Q3 2023 · Sep 30 | $18K | — | 91.9% | −$773K | −$660K | — | -0.21 | −$1.1M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $72K | 38.6% | −$4.3M | −$4.2M | -5863.5% | -0.50 | −$4.7M | — | — | — | — |
| FY2024 · to Dec 31 | $72K | 91.9% | −$4.7M | −$4.4M | -6092.6% | -1.19 | −$3.8M | — | — | — | — |
| FY2023 · to Dec 31 | $72K | 91.9% | −$3.9M | −$3.7M | -5132.6% | -1.20 | −$3.2M | — | — | — | — |
| FY2022 · to Dec 31 | $72K | 91.9% | −$3.6M | −$3.9M | -5420.9% | — | −$3.5M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$2.7M | $3.9M | — | 0.04 | −$2.3M | — | — | — | — |
| FY2020 · to Dec 31 | $41K | -330.4% | −$2.2M | −$3M | -7422.5% | -0.05 | −$1.2M | — | — | — | — |
Every number comes from Silo Pharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.